Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to ...
Cellares is partnering with Stanford Medicine to automate gene-edited stem cell therapy for HIV and more than 19 rare diseases.
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
Cellares, in collaboration with Mitsui Fudosan, a Japanese real estate developer, established Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under ...
Ori Biotech has lassoed a significant milestone for its space- and cost-efficient cell and gene therapy manufacturing platform. The FDA has granted the company’s IRO platform an Advanced Manufacturing ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
AZoLifeSciences on MSN
Machine learning model accelerates manufacturing timeline of monoclonal antibodies
As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results